Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Report on first EHA-SWG Scientific Meeting

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

EHA in the BioMed Alliance: joining forces for biomedical research

At a recent meeting at the European Parliament, Prof.

Recommendations for COVID-19

Is CBTH for me?

CBTH provides the development of computational biology skills for scholars who want to build successful careers in hematology research.

For mentors of applicants

As part of your support for the candidate applying for CBTH, the following is required from you:

Supervision and mentorship to be provided to the applicant during the CBTH award year.

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Is CRTH for me?

Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD 
Applicant must be actively employed in a hematology or hematology-related research environment 
The applicant must be an EHA member or EHA Guest at the time of application submission…

Young EHA Committee call for interest

The mission of the Young EHA Committee is to:

Represent the voice of young and early career hematologists and scientists within EHA
Engage these junior members in EHA and EHA-related events
Foster the Young EHA community within the field of hematology
This year, we…

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.